Prognosis
Astra-Oxford Vaccine Found Effective in Preventing Covid
- One regimen shows 90% efficacy, the other less protection
- Data follow positive Moderna, Pfizer vaccine trial results
This article is for subscribers only.
A Covid-19 vaccine developed by the University of Oxford and AstraZeneca Plc prevented a majority of people from getting the disease in a large trial, another promising development in the quest to end the pandemic, and the rollout could begin next month.
The vaccine stopped an average of 70% of participants from falling ill, an early analysis of the data show. The effectiveness rose to 90% for one of two regimens, using half a dose followed by a full one later, close to the high bar set by Pfizer Inc. and Moderna Inc.